Results 121 to 130 of about 6,748 (202)

The sponsor-proxy model: Bridging basic science discovery and investigator-initiated clinical trials. [PDF]

J Clin Transl Sci
Liu X, Shank D, Lü J, Joshi M.
europepmc   +1 more source

Dome-Shaped Macula Curvature: A New Quantitative Metric to Assess Dome-Shaped Macula Subtypes. [PDF]

Transl Vis Sci Technol
Del Fabbro S, Arrigo A, Bianco L, Antropoli A, Nunziata A, Introini U, Giusto D, Bandello F, Battaglia Parodi M.   +8 more
europepmc   +1 more source

Comparative Evaluation of Quantitative Real-Time PCR and a Laboratory-Developed Chip-Based Real-Time Digital PCR for <i>JAK2</i> V617F Allele Burden in Myeloproliferative Neoplasms. [PDF]

Diagnostics (Basel)
Park S, Kim K, Ha JS.
europepmc   +1 more source

Magnetic resonance-guided laser interstitial thermal therapy for mesial temporal lobe epilepsy (MINE): a single-centre, prospective, randomised, open-label, blinded-endpoint controlled trial protocol in China. [PDF]

BMJ Open
Mo J, Cai D, Zhou Q, Dong S, Li Q, Zhao B, Wang X, Zhang C, Hu W, Zheng Z, Sang L, Shao X, Zhang J, Zhu L, Wang Z, Wu Y, Wang A, Zhang K.   +17 more
europepmc   +1 more source

Nordic hip fracture registries: comparisons toward a minimal common and standardized Nordic Hip Fracture Dataset (Nordic-HFD). [PDF]

Acta Orthop
Schmidt CR, Palm H, Viberg B, Hedström M, Wolf O, Rogmark C, Gjertsen JE, Dybvik E, Pedersen AB.   +8 more
europepmc   +1 more source

SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. [PDF]

BMC Cancer
Eschen JT, Jensen LL, Hausmann D, Lind ANR, Lukacova S, Weischenfeldt J, Lassen U, Westphal M, Winkler F, Simonsen U, Korshoej AR.   +10 more
europepmc   +1 more source

Simultaneous spectrophotometric eco-friendly analysis of triple-drug H.pylori regimen (Vonoprazan, Amoxicillin, Metronidazole) for quality control and in vitro dissolution testing. [PDF]

Sci Rep
Hamdy AM, Abu-Bakr RI, El-Hay SSA, Sayed RA.   +3 more
europepmc   +1 more source

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). [PDF]

Trials
Mlyuka HJ, Liyoyo A, Nyaulingo B, Mpolya E, Kaswaga OL, Semvua H, Lwambura S, McHugh TD, Wildner L, Sabiiti W, Adegbite BR, Nliwasa M, Khosa C, Mbelele P, Mbeya B, Jeremiah K, Boeree MJ, Gillespie SH, Sloan DJ, Mpagama SG, SimpliciTB Consortium.   +20 more
europepmc   +1 more source

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection

Hollenbach J, Srivastava A, Chatzileontiadou D, Adhikari A, Suseno R, Lin S, Boquett J, Tuibeo J, Yusufali T, Peyser N, Farias T, Kichula K, Nguyen A, Jose I, Jayasinghe D, Leong S, Beatty A, Tarassi K, Kontou E, Maddumage J, Ampelakiotou K, Tsirogianni A, Dewar-Oldis M, Tu TM, Phan T, Barnard P, Sabatino J, Zoulas D, Ariens E, Mercer T, Grant E, D’Orsogna L, Smith C, Norman P, Marcus G, Olgin J, Pletcher MJ, Maiers M, Gras S.   +38 more
europepmc   +1 more source

Understanding pandemics through molecular gas dynamics. [PDF]

PNAS Nexus
Guan YY, Wang ZH.
europepmc   +1 more source